Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 9/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 2/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26432948 | 0.87 | CD38 (0.42) | CD38KMT2ANPC1RAB9AHSD17B10 | |
| SCHEMBL26432855 | 0.82 | KMT2A (0.47) | CD38KMT2AMEN1GRM5NPC1 | |
| SCHEMBL26432876 | 0.81 | CD38 (0.39) | CD38KMT2ANPC1RAB9AHSD17B10 | |
| SCHEMBL26432933 | 0.77 | TAF1 (0.39) | CD38KMT2AHSD17B10 | |
| SCHEMBL26432977 | 0.76 | L3MBTL1 (0.36) | KMT2AMEN1 | |
| SCHEMBL26432865 | 0.74 | PBK (0.39) | CD38NPC1HSD17B10 | |
| SCHEMBL26432887 | 0.74 | GRM5 (0.48) | CD38GRM5 | |
| SCHEMBL20612941 | 0.71 | TAS1R3 (0.54) | CD38NPC1RAB9A | |
| SCHEMBL20541577 | 0.69 | CHEK1 (0.50) | KMT2AMEN1GRM5IKBKBCHUK | |
| SCHEMBL988532 | 0.68 | KEAP1 (0.56) | GRM5IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638704-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638704-B2 | Bicyclic compounds and their use in the treatment of cancer | PTGER4, PTGER1, PTGER3 | CD38 1709/4885NR3C1 355/4885PGR 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.